期刊文献+

Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model 被引量:5

下载PDF
导出
摘要 AIM: To evaluate the antiviral potency of a new antihepatitis C virus(HCV) antiviral agent targeting the cellular autophagy machinery. METHODS: Non-infected liver slices, obtained from human liver resection and cut in 350 μm-thick slices(2.7 × 106 cells per slice) were infected with cell culture-grown HCV Con1b/C3 supernatant(multiplicity of infection = 0.1) cultivated for up to ten days. HCV infected slices were treated at day 4 post-infection with GNS-396 for 6 d at different concentrations. HCV replication was evaluated by strand-specific real-time quantitative reverse transcription- polymerase chain reaction. The infectivity titers of supernatants were evaluated by foci formation upon inoculation into naive Huh-7.5.1 cells. The cytotoxic effect of the drugs was evaluated by lactate dehydrogenase leakage assays. RESULTS: The antiviral efficacy of a new antiviral drug, GNS-396, an autophagy inhibitor, on HCV infection of adult human liver slices was evidenced in a dosedependent manner. At day 6 post-treatment, GNS-396 EC50 was 158 nmol/L without cytotoxic effect(compared to hydroxychloroquine EC50 = 1.17 μmol/L).CONCLUSION: Our results demonstrated that our ex vivo model is efficient for evaluation the potency of autophagy inhibitors, in particular a new quinoline derivative GNS-396 as antiviral could inhibit HCV infection in a dosedependent manner without cytotoxic effect. AIM: To evaluate the antiviral potency of a new antihepatitis C virus(HCV) antiviral agent targeting the cellular autophagy machinery. METHODS: Non-infected liver slices, obtained from human liver resection and cut in 350 μm-thick slices(2.7 × 106 cells per slice) were infected with cell culture-grown HCV Con1b/C3 supernatant(multiplicity of infection = 0.1) cultivated for up to ten days. HCV infected slices were treated at day 4 post-infection with GNS-396 for 6 d at different concentrations. HCV replication was evaluated by strand-specific real-time quantitative reverse transcription- polymerase chain reaction. The infectivity titers of supernatants were evaluated by foci formation upon inoculation into naive Huh-7.5.1 cells. The cytotoxic effect of the drugs was evaluated by lactate dehydrogenase leakage assays. RESULTS: The antiviral efficacy of a new antiviral drug, GNS-396, an autophagy inhibitor, on HCV infection of adult human liver slices was evidenced in a dosedependent manner. At day 6 post-treatment, GNS-396 EC50 was 158 nmol/L without cytotoxic effect(compared to hydroxychloroquine EC50 = 1.17 μmol/L).CONCLUSION: Our results demonstrated that our ex vivo model is efficient for evaluation the potency of autophagy inhibitors, in particular a new quinoline derivative GNS-396 as antiviral could inhibit HCV infection in a dosedependent manner without cytotoxic effect.
出处 《World Journal of Hepatology》 CAS 2016年第21期902-914,共13页 世界肝病学杂志(英文版)(电子版)
基金 Supported by The Institut National de la Sante et de la Recherche Medicale(INSERM,France) the personal support of Professor Jean-Francois Delfraissy as Director of the French Agency,Agence Nationale de Recherches sur le Sida et les hepatites virales(ANRS)
  • 相关文献

参考文献2

二级参考文献53

  • 1Lavanchy D. Evolving epidemiology of hepatitis C virus. ClinMicrobiol Infect 2011; 17: 107-115 [PMID: 21091831 DOI: 10.1111/j.1469-0691.2010.03432.x].
  • 2European Association for the Study of the Liver. EASL recommendationson treatment of hepatitis C 2014. J Hepatol 2014; 61:373-395 [PMID: 24818984 DOI: 10.1016/j.jhep.2014.05.001].
  • 3Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S,Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, DusheikoG, Marcellin P. The neglected hepatitis C virus genotypes 4, 5 and6: an international consensus report. Liver Int 2010; 30: 342-355[PMID: 20015149 DOI: 10.1111/j.1478-3231.2009.02188.x].
  • 4European Association for the Study of the Liver. EASL ClinicalPractice Guidelines: management of hepatitis C virus infection.J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023].
  • 5Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM,Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N,Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir forpreviously treated chronic HCV genotype 1 infection. N Engl JMed 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482].
  • 6Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM,Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R,George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM,Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, KauffmanRS, Zeuzem S. Telaprevir for previously untreated chronic hepatitisC virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID:21696307 DOI: 10.1056/NEJMoa1012912].
  • 7Poordad F, McCone J, Bacon BR, Bruno S, Manns MP,Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, BoparaiN, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, BronowickiJP. Boceprevir for untreated chronic HCV genotype 1 infection.N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI:10.1056/NEJMoa1010494].
  • 8Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S,Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, NevensF, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B,Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G,Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCVinfection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308DOI: 10.1056/NEJMoa1013086].
  • 9Rupp D, Bartenschlager R. Targets for antiviral therapy ofhepatitis C. Semin Liver Dis 2014; 34: 9-21 [PMID: 24782254DOI: 10.1055/s-0034-1371006].
  • 10Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, HassaneinT, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR,Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, HylandRH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT,McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvirfor previously untreated chronic hepatitis C infection. N Engl JMed 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853].

共引文献121

同被引文献15

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部